Using cyclic variation of integrated backscatter in cardiac ultrasound to evaluate the improvement of myocardial fibrosis by taking atorvastatin

• Main Authors: Yu Min Lin, 林育民
• Other Authors: S. J. Tu
• Format: Others
• Published: 2012
• Online Access: http://ndltd.ncl.edu.tw/handle/94878512492077682052

碩士 === 長庚大學 === 醫學影像暨放射科學系 === 100 === Background and Objective： Myocardial fibrosis represents the process of heart failure. Atorvastatin therapy attenuated cardiac fibrosis in experimental rat model of heart failure or myocardial infarction. However, the reasons have not yet been elucidated. This study determines the improvement of myocardial fibrosis by atorvastatin in vasculopathic patients detected by cyclic variation of integrated backscatter (CVIBS). Materials and Methods： Thirty-eight patients (29 men, 9 women, age 65±10.80 years) with vascular disease were allocated to atorvastatin treatment for 12 weeks. CVIBS and biochemical parameters were measured at baseline and 12 weeks after treatment. Results： Total cholesterol, triglycerides and low-density lipoprotein were significantly reduced in 38 patients. Only 21 patients (16 men, 5 women, age 64±9.84 years) were measured with cardiac echo, and the data of CVIBS were significantly elevated after atorvastatin treatment for twelve weeks. Fibrosis markers including tissue inhibitor of metalloproteinase-1 and amino-terminal propeptide of type III procollagen were also significantly reduced in these patients. Conclusion： Twelve weeks atorvastatin therapy improved cardiac fibrosis in this small, selected vasculopathic population detected with CVIBS and fibrosis markers. Further evaluation of atorcastatin therapy in the large number of vasculopathic patients with other related examination is warranted.